Posts by Magali Bischof

CSEM has contributed to the first dexterous and sentient hand prosthesis implant.   A female Swedish patient with hand amputation has become the first recipient of an osseo-neuromuscular implant to control a dexterous hand prosthesis. In a pioneering surgery, titanium implants were placed in the two forearm bones (radius and ulnar), from which electrodes to nerves…

Over 30 scientists from different Swiss universities have joined the newly launched Swiss stress network.   The network enables thorough research in the different stress-related fields helping acquire a better understanding of stress causes and consequences; hence offering more efficient treatment options.   Read more about this new initiative (EPFL article in English)

“Lonza invests 12% of its sales revenue in its plants” in Visp (VS).   Marc Funk will replace Richard Ridinger as CEO of Lonza as of 1 March 2019. He tells Patrice Delaye, from Bilan, how this investment will be used to support Lonza’s move from chemistry to biotechnology based services.   Read Magazine Bilan’s…

Congratulations to ChemAlive, the Lausanne (Vaud) based startup, who has just moved from its R&D to its business phase! “… The startup is now entering the business stage, offering an online computational chemistry platform that facilitates accurate predictive analytics using the state-of-the-art in modern physics, focused on process (synthesis) design in organic chemistry. Further, the startup…

SICHH contribue à une avancée dans la recherche des symptômes précoces de la maladie d’Alzheimer. L’équipe du Dr Alberi publie un manuscrit scientifique qui démontre pour la première fois que le nerf olfactif subit des altérations morphologiques précoces au développement de la démence.

The Swiss based startup, ADC Therapeutics, has dosed a solid tumor patient in its first Phase I clinical trial.   Read the SBA’s full article in English

“EPFL and UNIL scientists have discovered how a mutated gene can affect the three-dimensional interactions of genes in the cell, leading to various forms of cancer.” The mutation of the gene “EZH2” generates a modification of interactions within topologically associating domains (TADs) which in turn stimulates the development of tumors.   Read the full EPFL…

Research from EPFL and ETH Zurich has lead to the development of microrobots capable of changing shape to according to their surroundings. This advancement will enable a more efficient drug delivery by accessing precise and intricate areas of the human body.   Read EPFL’s full article in English.

Sophia Genetics closes it Series E funding round with a $77 million cash injection. The Swiss biotech is now used in over 850 hospitals, in 77 countries and supports the diagnosis of over 300’000 patients.   Read TechCrunch‘s full article in English

MindMaze, spin-off of the EPFL, has developed a neurological rehabilitation system called MindMotionPRO. This system supports patients in their recovery from a stroke using artificial intelligence. MindMotionPro has pushed MindMaze to be worth over 1 billion dollars and hence converting its startup status to become the first Swiss unicorn.   Read Innovaud‘s full article and link to…